eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
 
3/2008
vol. 46
 
Share:
Share:
more
 
 
abstract:

REVIEW PAPER
Treatment options for patients with rheumatoid arthritis after inadequate response to tumour necrosis factor inhibitors

Piotr Wiland

Reumatologia 2008; 46, 3: 159–167
Online publish date: 2008/07/09
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Tumour necrosis factor (TNF-α) inhibitors have improved the clinical outcome of many patients with rheumatoid arthritis (RA). However, some patients do not respond well or have contraindications to these agents. The appropriate treatment strategy in refractory RA would be possible by optimizing concomitant conventional disease modifying antirheumatic drugs, increasing the dose of TNF-α inhibitor or shortening the dosing frequency, switching to another TNF-α inhibitor or switching to other new biological agents available for use in patients with RA such as abatacept or rituximab.
keywords:

rheumatoid arthritis, inadequate response to tumor necrosis factor inhibitors, infliximab, etanercept, adalimumab, abatacept, rituximab



Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe